Cargando…
Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis
Aortic valve stenosis (AVS) is the most prevalent valvular heart disease in the Western World with exponentially increased incidence with age. If left untreated, the yearly mortality rates increase up to 25%. Currently, no effective pharmacological interventions have been established to treat or pre...
Autores principales: | Schnitzler, Johan G., Ali, Lubna, Groenen, Anouk G., Kaiser, Yannick, Kroon, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995555/ https://www.ncbi.nlm.nih.gov/pubmed/31766423 http://dx.doi.org/10.3390/biom9120760 |
Ejemplares similares
-
Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis
por: Kaiser, Yannick, et al.
Publicado: (2022) -
Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis
por: Zheng, Kang H., et al.
Publicado: (2019) -
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification( )
por: Kaiser, Yannick, et al.
Publicado: (2022) -
Lipoprotein(a) and progression of aortic valve calcification: a case of collider bias? Reply
por: Kaiser, Yannick, et al.
Publicado: (2023) -
Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis
por: Bourgeois, Raphaëlle, et al.
Publicado: (2020)